Lyophilization: A Primer - Optimized freeze-drying cycles can offer scientific and business advantages. - BioPharm International

ADVERTISEMENT

Lyophilization: A Primer
Optimized freeze-drying cycles can offer scientific and business advantages.


BioPharm International
Volume 26, Issue 3, pp. 46-51


Katriona Scoffin
Freeze drying, or lyophilization, is a stabilization method that is widely used in the pharmaceutical industry for drugs, vaccines, antibodies, and other biological material. Because the product is dried without excessive heating, proteins and other products that would be thermally denatured can be successfully preserved without loss of activity.

Freeze-dried products have a very high surface area, which enables them to be reconstituted quickly. This quick reconstitution is particularly important in the case of emergency vaccines and antibodies, which need to be administered as soon as possible.

Every formulation has different freeze-drying characteristics and, therefore, different processing requirements. To ensure cycles are both robust and efficient, they should be tailor-made for each formulation. Failure to do so can lead to inconsistent dryness across samples, reduced stability during storage, and reduced activity on rehydration.

There are three main business advantages of optimizing a product's lyophilization cycle:
  • Financial gain: optimal lyophilization cycles use only the energy and time required, shortening process time and increasing product throughput.
  • Product excellence: a well-dried product exhibits a long shelf life and maximum activity on rehydration.
  • Quality and regulatory assurance: consistency throughout batches is assured and regulatory submissions are completed with the inclusion of lyophilization cycle data.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
FDA Develops Alternative Assay to Increase Availability of Influenza Vaccines
April 10, 2014
Merck Announes Management Changes
April 7, 2014
Author Guidelines
Source: BioPharm International,
Click here